Short answer
Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on May 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for quarter ended March 31, 2026.
Arbutus Biopharma Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains results and additional company information
- Investor focus: quarterly operating performance, cash position, and pipeline updates in the accompanying release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arbutus Biopharma Corp 8-K filings
Get the next ABUS 8-K as it lands
Follow ABUS for push alerts, or ask the research agent what this filing means.